Production and evaluation of cellular effects of 153Sm-DOTA-cetuximab and 177Lu-DOTA-cetuximab radioconjugates
Author(s):
Article Type:
Research/Original Article (دارای رتبه معتبر)
Abstract:
Antibody-based radiopharmaceuticals are of increasing interest today in cancer imaging and radiotherapy. The cetuximab monoclonal antibody binds to the epidermal growth factor receptor (EGFR) and thus provides therapeutic and diagnostic protocols against this receptor. Following purification and conjugation with freshly prepared DOTA-NHS, the cetuximab antibody was labeled with lutetium 177 and samarium chloride-153. Labeling efficiency and in vitro stability were measured using thin-layer chromatography. Cellular tests were performed to determine radioimmunoactivity in cancer cells. The results showed that the labeling efficiencies of 177Lu-DOTA-cetuximab and 153Sm-DOTA-cetuximab were more than 97±1% and 96±2%, respectively. Also, the in vitro stability of the labeled products in fresh human serum after 96 hours was 83± 22% and 78%, respectively. Immunoreactivity was 91% for 177Lu-DOTA-cetuximab and 66±1% for 153Sm-DOTA-cetuximab. With different intensities based on time and beta energy, both products inhibited the growth of HT29 colon cancer cells. The results showed that the immunoconjugate complexes of 177Lu-DOTA-cetuximab and 153Sm-DOTA-cetuximab can be considered a novel radiopharmaceutical for cancer radioimmunotherapy.
Keywords:
Language:
Persian
Published:
Journal of Nuclear Science and Tehnology, Volume:44 Issue: 3, 2023
Pages:
171 to 179
https://magiran.com/p2561790
دانلود و مطالعه متن این مقاله با یکی از روشهای زیر امکان پذیر است:
اشتراک شخصی
با عضویت و پرداخت آنلاین حق اشتراک یکساله به مبلغ 1,390,000ريال میتوانید 70 عنوان مطلب دانلود کنید!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی نامحدود همه کاربران به متن مطالب تهیه نمایند!
توجه!
- حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران میشود.
- پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانههای چاپی و دیجیتال را به کاربر نمیدهد.
In order to view content subscription is required
Personal subscription
Subscribe magiran.com for 70 € euros via PayPal and download 70 articles during a year.
Organization subscription
Please contact us to subscribe your university or library for unlimited access!